Summit Therapeutics Inc.

11/16/2026 | Press release | Distributed by Public on 11/16/2026 19:26

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
DUGGAN ROBERT W
2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [SMMT]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Co-Chief Executive Officer
(Last) (First) (Middle)
C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE SUITE 1000
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
(Street)
MIAMI, FL 33131
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/16/2026 M(1) 500,000 A $1.06 531,000(2) I By Spouse
Common Stock 573,883,879 D
Common Stock 25,824,474(2) I By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee
Common Stock 76,680(2) I Immediate family member of Spouse
Common Stock 10,199,776(2) I By the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $1.06 11/16/2026 M(1) 500,000 (3) 06/28/2032 Common Stock 500,000 $ 0 800,000 I By Spouse

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
DUGGAN ROBERT W
C/O SUMMIT THERAPEUTICS INC.
601 BRICKELL KEY DRIVE SUITE 1000
MIAMI, FL 33131
X X Co-Chief Executive Officer

Signatures

/s/ Robert W. Duggan 11/16/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On November 16, 2026, the Spouse of Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.
(2) The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
(3) The option was granted to the Spouse of Reporting Person on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Summit Therapeutics Inc. published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 17, 2026 at 01:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]